Search Result

Results for "

PLA2 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) AMPK (1) Antibiotic (1) AP-1 (1) Apoptosis (7) Atg4 (1) Autophagy (2) Bacterial (1) Bcl-2 Family (1) Biochemical Assay Reagents (1) c-Met/HGFR (1) Cathepsin (1) COX (3) DAGL (1) DGK (1) Drug Derivative (1) Endogenous Metabolite (2) Environmental Pollutants (3) FAP (1) Fungal (3) HRASLS (1) Integrin (4) Interleukin Related (1) Keap1-Nrf2 (1) MAGL (1) Mitochondrial Metabolism (1) MMP (1) mTOR (1) NADPH Oxidase (1) NF-κB (2) NO Synthase (1) Oxidative Phosphorylation (1) p38 MAPK (1) Parasite (1) Phosphatase (2) Phospholipase (64) PI3K (1) PKC (1) Prostaglandin Receptor (2) Reactive Oxygen Species (ROS) (2) Reference Standards (6) Src (1) STAT (1) TRP Channel (1)
By Research Areas:	Cancer (11) Cardiovascular Disease (11) Infection (6) Inflammation/Immunology (34) Metabolic Disease (12) Neurological Disease (17)

By Targets:

Akt (2)

AMPK (1)

Antibiotic (1)

AP-1 (1)

Apoptosis (7)

Atg4 (1)

Autophagy (2)

Bacterial (1)

Bcl-2 Family (1)

Biochemical Assay Reagents (1)

c-Met/HGFR (1)

Cathepsin (1)

COX (3)

DAGL (1)

DGK (1)

Drug Derivative (1)

Endogenous Metabolite (2)

Environmental Pollutants (3)

FAP (1)

Fungal (3)

HRASLS (1)

Integrin (4)

Interleukin Related (1)

Keap1-Nrf2 (1)

MAGL (1)

Mitochondrial Metabolism (1)

MMP (1)

mTOR (1)

NADPH Oxidase (1)

NF-κB (2)

NO Synthase (1)

Oxidative Phosphorylation (1)

p38 MAPK (1)

Parasite (1)

Phosphatase (2)

Phospholipase (64)

PI3K (1)

PKC (1)

Prostaglandin Receptor (2)

Reactive Oxygen Species (ROS) (2)

Reference Standards (6)

Src (1)

STAT (1)

TRP Channel (1)

By Research Areas:

Cancer (11)

Cardiovascular Disease (11)

Infection (6)

Inflammation/Immunology (34)

Metabolic Disease (12)

Neurological Disease (17)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Targets Recommended: PNPLA3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10521

Darapladib Maximum Cited Publications 7 Publications Verification SB-480848	Phospholipase Apoptosis	Cardiovascular Disease Cancer
Darapladib (SB-480848) is an orally active, selective and reversible *Lp-PLA2* inhibitor (IC₅₀=0.25 nM). Darapladib can trigger irreversible actions on glioma cell apoptosis and induce cycle arrest. Darapladib can be used in the study of atherosclerosis and cancer .

HY-118628

(E/Z)-BML264 Maximum Cited Publications 7 Publications Verification N-(p-Amylcinnamoyl) anthranilic acid; ACA	Phospholipase TRP Channel	Cardiovascular Disease
(E/Z)-BML264 (N-(p-amylcinnamoyl) Anthranilic Acid) is a broad spectrum Phospholipase A₂ (PLA₂) inhibitor and TRP channel blocker . (E/Z)-BML264 (N-(p-amylcinnamoyl) Anthranilic Acid) is also an effective reversible inhibitor of calcium-activated chloride channels, has potential to treat arrhythmia .

HY-18570

1-Naphthaleneacetic acid 1 Publications Verification 1-Naphthylacetic acid	Environmental Pollutants Phospholipase	Others
1-Naphthaleneacetic acid (1-Naphthylacetic acid), a auxin, can promote plant growth. 1-Naphthaleneacetic acid is also an inhibitor of *PLA₂, with an IC₅₀* of 13.16 μM .

HY-17448

Varespladib methyl 1 Publications Verification A-002; LY333013	Phospholipase	Inflammation/Immunology
Varespladib methyl (A-002; LY333013) is a selective inhibitor of group II secretory phospholipase A2 (PLA2).

HY-11059

KH064	Phospholipase	Inflammation/Immunology
KH064, a D-tyrosine derivative, is an orally active, potent secretory phospholipase A₂ (sPLA₂) inhibitor with an IC₅₀ of 29 nM for human nonpancreatic secretory PLA₂ isoform IIa (hnpsPLA₂-IIa). KH064 has anti-inflammatory activity .

HY-18540

KT109 1 Publications Verification	MAGL DAGL	Metabolic Disease Inflammation/Immunology
KT109 is a potent and an isoform-selective inhibitor of diacylglycerol lipase-β (DAGLβ) with an IC₅₀ of 42 nM. KT109 has ~60-fold selectivity for DAGLβ over DAGLα. KT109 shows inhibitory activity against PLA2G7 (IC₅₀=1 µM). KT109 shows negligible activity against FAAH, MGLL, ABHD11, and cytosolic phospholipase A2 (cPLA2 or PLA2G4A). KT109 perturbs a lipid network involved in macrophage inflammatory responses and lowers 2-Arachidonoylglycerol (HY-W011051), Arachidonic acid (HY-109590) and eicosanoids in mouse peritoneal macrophages .

HY-115062

MJ33 lithium salt	Phospholipase NADPH Oxidase p38 MAPK Akt NF-κB AP-1 Reactive Oxygen Species (ROS)	Cardiovascular Disease Inflammation/Immunology Cancer
MJ-33 lithium salt is a competitive phospholipase A₂ (PLA₂) inhibitor with an IC₅₀ of 0.3 μM. MJ-33 lithium salt inhibits NOX2 activation and reduces ROS production by blocking the PLA₂ activity of Prdx6. MJ-33 lithium salt effectively inhibits the activity of acidic PLA₂ (pH 4.0) and reduces the degradation of alveolar surfactant phosphatidylcholine (PC), but exerts no effect on alkaline PLA₂ (pH 8.5). MJ-33 lithium salt significantly alleviates lung oxidative injury induced by ischemia-reperfusion (I/R). MJ-33 lithium salt significantly inhibits the invasion, migration and adhesion abilities of prostate cancer cells by suppressing the MAPK, AKT, NF-κB and AP-1 signaling pathways. MJ-33 lithium salt can be used for the research of ROS-related diseases and prostate cancer .

HY-123070

ONO-RS-082	Phospholipase	Inflammation/Immunology
ONO-RS-082 is an inhibitor of phospholipase A (PLA) . ONO-RS-082 inhibits *PLA2* with the IC₅₀ of 1.0 μM, but does not inhibit PLC even at 100 μM .

HY-18570A

1-Naphthaleneacetic acid potassium salt 1 Publications Verification Potassium 1-Naphthaleneacetate	Environmental Pollutants Phospholipase	Others
1-Naphthaleneacetic acid potassium salt (Potassium 1-Naphthaleneacetate), a synthetic auxin, can promote plant growth. 1-Naphthaleneacetic acid potassium salt is also an inhibitor of *PLA₂, with an IC₅₀* of 13.16 μM .

HY-102004

Rilapladib 3 Publications Verification SB 659032	Phospholipase	Neurological Disease Inflammation/Immunology
Rilapladib (SB 659032) is a selective *Lp-PLA₂* (lipoprotein-associated phospholipase A₂) inhibitor with an IC₅₀ of 230 pM . Rilapladib (SB 659032) is also a PAFR (Platelet Activating Factor Receptor) antagonist .

HY-19151

Fuzapladib IS-741	Integrin Phospholipase	Inflammation/Immunology
Fuzapladib (IS-741), an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site .

HY-156041

Lysophosphatidylethanolamines, egg Lyso-PE (egg); LPE (egg); L-α-lysophosphatidylethanolamine	Endogenous Metabolite	Metabolic Disease
Lysophosphatidylethanolamine (LPE) is a naturally-occurring lysophospholipid that can be generated via deacylation of phosphatidylethanolamine by phospholipase A2 (PLA2). It increases the phosphorylation of ERK1/2 in PC12 cells, an effect that can be blocked by the MEK inhibitors U-0126 (HY-12031A) and PD 98059 (HY-12028) and the EGFR inhibitor AG-1478 (HY-13524).1 LPE also increases neurite outgrowth and expression of neurofilament M in PC12 cells. LPE inhibits the activity of phospholipase D (PLD) partially purified from cabbage.3 This product contains lysophosphatidylethanolamine molecular species with variable fatty acyl chain lengths at the sn-1 position and a hydroxy group at the sn-2 position.

HY-101015A

OBAA	Phospholipase Apoptosis	Inflammation/Immunology
OBAA is a potent phospholipase A2 (PLA2) inhibitor with an IC₅₀ of 70 nM. OBAA blocks Melittin-induced Ca ²⁺ influx in Trypanosoma brucei with an IC₅₀ of 0.4 μM .

HY-101195

DL-erythro-Dihydrosphingosine	PKC Phospholipase Bcl-2 Family Apoptosis MMP	Inflammation/Immunology Cancer
DL-erythro-Dihydrosphingosine is a sphingosine-based PKC inhibitor. DL-erythro-Dihydrosphingosine directly inhibits the enzymatic activity of *PLA2. DL-erythro-Dihydrosphingosine inhibits* the activity of Bcl-2 protein involved in apoptosis. DL-erythro-Dihydrosphingosine inhibits the activity of matrix metalloproteinases (MMP). DL-erythro-Dihydrosphingosine is applicable for research on cancer and inflammatory diseases .

HY-19757

Lp-PLA2-IN-1	Phospholipase	Cardiovascular Disease Neurological Disease
Lp-PLA2-IN-1 is a potent Lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2-IN-1 has the potential for atherosclerosis, Alzheimer's disease research .

HY-145653

GSK2647544	Phospholipase	Cardiovascular Disease Neurological Disease Inflammation/Immunology
GSK2647544 is an orally available, selective inhibitor of *Lp-PLA2. Lipoprotein-associated phospholipase (Lp-PLA2*) is a calcium-independent phospholipase A2 with proinflammatory activities that is primarily secreted by monocyte-derived macrophages .

HY-19415

SB-435495	Phospholipase	Metabolic Disease
SB-435495 is a potent, selective, reversible, non-covalent and orally active *Lp-PLA₂* inhibitor with an IC₅₀ of 0.06 nM .

HY-108609

YM-26734	Phospholipase	Inflammation/Immunology
YM-26734 is a competitive inhibitor of secretory phospholipase A ² (PLA ²) that exhibits a broad inhibitory profile to several PLA2s .

HY-144636

Atg4B-IN-2	Atg4 Cathepsin Phospholipase Autophagy	Cancer
Atg4B-IN-2 is a potent competitive Atg4B inhibitor with K_i value of 3.1 μM, also possesses declining *PLA₂* inhibitory potency, IC₅₀s of 11 μM and 3.5 μM for Atg4B and PLA₂, respectively. Atg4B-IN-2 enhances the anticancer activity of anti-castration-resistant prostate cancer agents via autophagy inhibition .

HY-W012595A

trans-Benzylideneacetone trans-Benzalacetone	Environmental Pollutants Phospholipase	Inflammation/Immunology
trans-Benzylideneacetone (trans-Benzalacetone), a metabolite of gram-negative entomopathogenic bacterium Xenorhabdus nematophila, is an enzyme inhibitor against phospholipase A2 (PLA2). trans-Benzylideneacetone is an immunosuppressant .

HY-N8213

Rapanone	Apoptosis Phospholipase Bacterial Parasite	Infection Inflammation/Immunology Cancer
Rapanone is a natural benzoquinone. Rapanone exhibits a broad spectrum of biological actions, including anti-tumor, antioxidant, anti-inflammatory, antibacterial and antiparasitic. Rapanone also is a potent and selective human synovial PLA₂ inhibitor, with an IC₅₀ of 2.6 μM .

HY-19151A

Fuzapladib sodium IS-741 sodium	Integrin Phospholipase	Inflammation/Immunology
Fuzapladib (IS-741) sodium, an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib sodium is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib sodium exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site .

HY-125254

LEI110 1 Publications Verification	Phospholipase HRASLS	Infection Metabolic Disease
LEI110 is a potent, selective and cell-permeable pan-inhibitor of the HRASLS family of thiol hydrolases. LEI110 inhibits *PLA2G16, HRASLS2, RARRES3* and iNAT, with pIC₅₀ values of 7.0, 6.8, 6.8, and 7.6, respectively. LEI110 reduces cellular arachidonic acid levels and oleic acid-induced lipolysis in HepG2 cells .

HY-W127380

Arachidonoyl thio-PC	Biochemical Assay Reagents	Others
Arachidonoyl Thio-PC is a substrate of many phospholipase A2 (PLA2), including sPLA2, cPLA2 and iPLA2. Cleavage of sn-2 fatty acids by PLA2 results in the production of free thiols, which react with chromogenic reagents such as DTNB (Ellman's reagent) and DTP, allowing quantification of PLA2 activity. Isozyme-specific cPLA2 activity can be measured by depleting or inhibiting sPLA2 and iPLA2 activity in the assay.

HY-129944

MJ33-OH	Phospholipase	Inflammation/Immunology
MJ33-OH is a metabolite of MJ33. MJ33 is an active-site-directed, specific, competitive, and reversible phospholipase A2 (PLA2) inhibitor. MJ33 blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6 .

HY-153559

Lp-PLA2-IN-13	Phospholipase	Neurological Disease
Lp-PLA2-IN-13 (compound 15) is a potent *Lp-PLA2* inhibitor. Lp-PLA2-IN-13 has the potential for the research of neurodegenerative related diseases .

HY-153560

Lp-PLA2-IN-14	Phospholipase	Neurological Disease
Lp-PLA2-IN-14 (Compound 19) is an *Lp-PLA2* inhibitor with a pIC₅₀ of 8.4 against rhLp-PLA2. Lp-PLA2-IN-14 can be used for the research of neurodegenerative related diseases, such as Alzheimer Disease (AD), glaucoma, age-related macular degeneration (AMD) or cardiovascular diseases including atherosclerosis and the like .

HY-153561

Lp-PLA2-IN-15	Phospholipase	Neurological Disease
Lp-PLA2-IN-15 (example 2) is a lipoprotein-associated phospholipase A2 (Lp-PLA 2) inhibitor, which can be used in the research of Alzheimer's disease, etc .

HY-N1450

Aristolochic acid C	Phospholipase	Cancer
Aristolochic acid C is a derivative of Aristolochic acid. Aristolochic acid is a phospholipase A₂ (PLA2) inhibitor, which disrupts cortical microtubule arrays and root growth in Arabidopsis .

HY-19415B

SB-435495 ditartrate	Phospholipase	Metabolic Disease
SB-435495 ditartrate is a potent, selective, reversible, non-covalent and orally active *Lp-PLA₂* inhibitor with an IC₅₀ of 0.06 nM .

HY-N8610

Uralsaponin D	Phosphatase	Inflammation/Immunology
Uralsaponin D is a saponin that can be isolated from Glycyrrhiza inflata. Uralsaponin D inhibits phospholipase A2 (PLA₂) with an IC₅₀ value of 32.2 μM .

HY-113560

Plipastatin B1	Antibiotic Fungal Phospholipase	Infection
Plipastatin B1 is a lipopeptide antibiotic, an inhibitor of phospholipase A₂ (PLA2), which has antifungal activity .

HY-23909

7,7-Dimethyl-(5Z,8Z)-eicosadienoic acid DEDA	Phospholipase	Inflammation/Immunology
7,7-Dimethyl-(5Z,8Z)-eicosadienoic acid (DEDA), a phospholipase inhibitor, is a non-metabolizable analog of arachidonic or eicosadienoic acid. 7,7-Dimethyl-(5Z,8Z)-eicosadienoic acid (DEDA) inhibits P388D1 cell phospholipase A₂ (PLA₂) (IC₅₀ = 16 µM) and snake venom PLA₂ (IC₅₀ = 14 µM) .

HY-128762

ML256	Phospholipase	Cancer
ML256 is a covalent lipoprotein-associated phospholipase A2 (Lp-PLA2 inhibitor. ML256 can be used for the study of neoplasms harboring a constitutively active variant of one or both of KRAS or HRAS .

HY-118725

Luffariellolide	Phospholipase	Inflammation/Immunology
Luffariellolide is an inhibitor of human synovial fluid phospholipase A2 (HSF-PLA2) (IC₅₀=5 μM). Luffariellolide effectively inhibits phorbol ester (PMA)-induced ear edema (ED₅₀=50 μg/ear) .

HY-129944A

MJ33-OH lithium	Phospholipase	Inflammation/Immunology
MJ33-OH lithium is a metabolite of MJ33. MJ33 is an active-site-directed, specific, competitive, and reversible phospholipase A2 (PLA2) inhibitor. MJ33 blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6 .

HY-101015

(2E)-OBAA	Phospholipase Apoptosis	Inflammation/Immunology
(2E)-OBAA is a potent phospholipase A2 (PLA2) inhibitor, with an IC₅₀ of 70 nM. (2E)-OBAA induces apoptosis of HUVEC cells. (2E)-OBAA blocks Melittin-induced Ca ²⁺ influx in Trypanosoma brucei, with an IC₅₀ of 0.4 μM .

HY-N14103

Cinatrin C1	Phospholipase	Others
Cinatrin C1 is a phospholipase A2 (PLA2) inhibitor that can be extracted from Circinotrichum falcatisporum RF-641 .

HY-122949

Momordicine I 2 Publications Verification	Apoptosis Autophagy DGK Mitochondrial Metabolism NO Synthase PI3K Akt Interleukin Related Src AMPK mTOR NF-κB c-Met/HGFR STAT Keap1-Nrf2 Reactive Oxygen Species (ROS) Oxidative Phosphorylation Endogenous Metabolite	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Momordicine I is a cucurbitane-type triterpenoids. Momordicine I suppresses glioma growth by promoting apoptosis and impairing mitochondrial oxidative phosphorylation. Momordicine I inhibits glycolysis, lipid metabolism, induces autophagy in HNC cells to suppress head and neck cancer growth. Momordicine I alleviates isoproterenol-induced cardiomyocyte hypertrophy through suppression of *PLA2G6* and DGK-ζ. Momordicine I exerts its cardiovascular benefits by upregulating nitric oxide, inhibiting the activity of angiotensin-converting enzyme (ACE), activating the PI3K/Akt pathway, reducing oxidative stress and inflammation. Momordicine I inhibits AKT1, IL-6, and SRC, suggesting its potential application in type 2 diabetes .

HY-N14104

Cinatrin C2	Phospholipase	Others
Cinatrin C2 is a phospholipase A2 (PLA2) inhibitor with an IC₅₀ of 800 μM and can be extracted from Circinotrichum falcatisporum RF-641 .

HY-N14105

Cinatrin C3	Phospholipase	Others
Cinatrin C3 is a phospholipase A2 (PLA2) inhibitor with an IC₅₀ of 70 μM and can be extracted from Circinotrichum falcatisporum RF-641 .

HY-173335

PLA2-IN-1	Phospholipase	Infection
PLA2-IN-1 (Compound 7) is a potent and selective inhibitor of phospholipase A₂ (PLA₂) with an IC₅₀ value of 1 nM PLA2-IN-1 inhibits PLA₂-induced coagulopathy in vitro. PLA2-IN-1 is promising for research of snakebite envenomation caused by cobra venom .

HY-160637

Lp-PLA2-IN-17	Phospholipase	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Lp-PLA2-IN-17 (Compound 39) is an inhibitor of *Lp-PLA₂. Lp-PLA2-IN-17 can be used to study disorders involving the hydrolysis of oxidized lipids into two inflammatory substances with the participation of Lp-PLA₂* .

HY-142777

Lp-PLA2-IN-9	Phospholipase	Neurological Disease
Lp-PLA2-IN-9 (compound 17), a tetracyclic pyrimidinone compound, is a potent *Lp-PLA2* inhibitor with a pIC₅₀ of 10.1 for rhLp-PLA2. Lp-PLA2-IN-9 has the potential for neurodegenerative related diseases research .

HY-142774

Lp-PLA2-IN-6	Phospholipase	Neurological Disease
Lp-PLA2-IN-6 (compound 18), a tetracyclic pyrimidinone compound, is a potent *Lp-PLA2* inhibitor with a pIC₅₀ of 10.0 for rhLp-PLA2. Lp-PLA2-IN-6 has the potential for neurodegenerative related diseases research .

HY-133148

Lp-PLA2-IN-2	Phospholipase	Inflammation/Immunology
Lp-PLA2-IN-2 is a potent and selective lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC₅₀ 0f 120 nM for recombinant human Lp-PLA2 .

HY-133149

Lp-PLA2-IN-3	Phospholipase	Cardiovascular Disease
Lp-PLA2-IN-3 is a potent and orally bioavailable lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC₅₀ of 14 nM for recombinant human Lp-PLA2 (rhLpPLA2) .

HY-142670

Lp-PLA2-IN-5	Phospholipase	Neurological Disease Metabolic Disease
Lp-PLA2-IN-5 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-5 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2021228159A1, compound 32) .

HY-142669

Lp-PLA2-IN-4	Phospholipase	Neurological Disease Metabolic Disease
Lp-PLA2-IN-4 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-4 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2021228159A1, compound 38) .

HY-142779

Lp-PLA2-IN-11	Phospholipase	Neurological Disease Metabolic Disease
Lp-PLA2-IN-11 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-11 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2014114249A1, compound E145) .

Cat. No.	Product Name	Type

HY-18570

1-Naphthaleneacetic acid 1 Publications Verification 1-Naphthylacetic acid	Biochemical Assay Reagents
1-Naphthaleneacetic acid (1-Naphthylacetic acid), a auxin, can promote plant growth. 1-Naphthaleneacetic acid is also an inhibitor of *PLA₂, with an IC₅₀* of 13.16 μM .

HY-W127380

Arachidonoyl thio-PC

Biochemical Assay Reagents

Arachidonoyl Thio-PC is a substrate of many phospholipase A2 (PLA2), including sPLA2, cPLA2 and iPLA2. Cleavage of sn-2 fatty acids by PLA2 results in the production of free thiols, which react with chromogenic reagents such as DTNB (Ellman's reagent) and DTP, allowing quantification of PLA2 activity. Isozyme-specific cPLA2 activity can be measured by depleting or inhibiting sPLA2 and iPLA2 activity in the assay.

HY-18570R

1-Naphthaleneacetic acid (Standard) 1-Naphthylacetic acid (Standard)	Biochemical Assay Reagents
1-Naphthaleneacetic acid (Standard) is the analytical standard of 1-Naphthaleneacetic acid. This product is intended for research and analytical applications. 1-Naphthaleneacetic acid (1-Naphthylacetic acid), a auxin, can promote plant growth. 1-Naphthaleneacetic acid is also an inhibitor of PLA2, with an IC50 of 13.16 μM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

PLA2 inhibitor

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Natural
Products